Exploring the post-translational modifications of a key protein in Parkinson's disease, researchers uncover potential pathways for future therapies in neurodegenerative diseases in general.

Neurodegenerative diseases, such as Alzheimer's and Parkinson's, present a significant health challenge, affecting over 50 million people globally. One common feature of these diseases is the ...

Researchers found that peristaltic pump flow mechanically breaks supersaturation to induce amyloid formation by hen egg white lysozyme, a-synuclein, amyloid b 1-40, and b2-microglobulin. The high ...

People whose cognitive symptoms were more severe than their biological Alzheimer's stage often had additional pathologies. Alpha-synuclein, TDP-43 signatures, and cerebral small vessel disease were ...

A new scientific report reveals that the protein aggregates associated with Parkinson’s disease are not inert clumps of cellular waste, but rather are chemically active structures that can ...

Annovis will likely announce results from it Parkinson's disease and Alzheimer's disease trials in the next couple of month. Annovis inhibits the formation of the amyloid precursor protein. The ...

Alzheimer’s disease is a long, slow neurodegenerative calamity, and scientists are still hunting for blood biomarkers that reflect all its specific stages. At the Clinical Trials on Alzheimer’s ...

A small new trial published in the journal Nature Medicine describes what would be two firsts for Parkinson's disease, if they pan out: a diagnostic test and a potential immune-based treatment that ...